228 related articles for article (PubMed ID: 35460398)
1. Regulatory aspects of biological medicines in Bosnia and Herzegovina.
Tubić B; Jungić S
Bosn J Basic Med Sci; 2022 Jul; 22(4):511-522. PubMed ID: 35460398
[TBL] [Abstract][Full Text] [Related]
2. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
[TBL] [Abstract][Full Text] [Related]
3. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
Crespi-Lofton J; Skelton JB
J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
[TBL] [Abstract][Full Text] [Related]
4. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
[TBL] [Abstract][Full Text] [Related]
5. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance and biosimilars: considerations, needs and challenges.
Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
[TBL] [Abstract][Full Text] [Related]
7. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
9. Biosimilar medical products - licensing, pharmacovigilance and interchangeability.
Grozdanova A; Netkovska KA; Sterjev Z; Naumovska Z; Zarevski R; Dimovski A; Suturkova L
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016; 37(1):27-36. PubMed ID: 27442414
[TBL] [Abstract][Full Text] [Related]
10. A place for biosimilars in the changing multiple sclerosis treatment landscape.
Greenberg B; Giovannoni G
Mult Scler Relat Disord; 2023 Sep; 77():104841. PubMed ID: 37467536
[TBL] [Abstract][Full Text] [Related]
11. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
Declerck P; Danesi R; Petersel D; Jacobs I
Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
[TBL] [Abstract][Full Text] [Related]
12. Opportunities and challenges in biosimilar uptake in oncology.
Dolan C
Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
[TBL] [Abstract][Full Text] [Related]
13. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
Jahnz-Rozyk K; Wiesik-Szewczyk E;
Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
15. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars: biologics that meet patients' needs and healthcare economics.
McCamish M; Yoon W; McKay J
Am J Manag Care; 2016 Sep; 22(13 Suppl):S439-S442. PubMed ID: 28719221
[TBL] [Abstract][Full Text] [Related]
17. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars: A Multidisciplinary Perspective.
Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
[TBL] [Abstract][Full Text] [Related]
19. A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN.
Dolinar R; Lavernia F; Edelman S
Endocr Pract; 2018 Feb; 24(2):195-204. PubMed ID: 29466056
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars 101: considerations for U.S. oncologists in clinical practice.
Camacho LH; Frost CP; Abella E; Morrow PK; Whittaker S
Cancer Med; 2014 Aug; 3(4):889-99. PubMed ID: 24810680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
